Biogen (BIIB) PT Lowered to $195 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen's (BIIB) Aduhelm Access Will be Significantly Limited, Company's Future Rests on lecanemab Data - Analysts
January 12, 2022 6:46 AM ESTYesterday, on January 11th, 2022, CMS posted a draft NCD proposing to cover approved anti-amyloid antibodies for Alzheimer's Disease under CED (coverage with evidence development) and only a randomized controlled trials.
Biogen's (NASDAQ: BIIB) Aduhelm is currently the only FDA approved therapy for Alzheimer's Disease, and such strict coverage rules are expected to significantly limit access to the drug.
Mizuho analyst Salim Syed removes nearly all Aduhelm sales from his model, as he lowers the price target on... More
Biogen (BIIB) PT Lowered to $292 at Needham & Company
January 12, 2022 6:27 AM ESTNeedham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $328.00) while maintaining a Buy rating.
The analyst commented, "Following CMS's draft decision to cover monoclonal antibodies for treatment of Alzheimers disease under Coverage with Evidence... More
